MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Current perspectives on TRK fusion-positive thyroid cancers

Clinical summary video and slides

Prof. Ezra Cohen

In this 5-min video update, Prof. Ezra Cohen summarises current perspectives on the diagnosis and treatment of TRK fusion-positive cancers. He discusses US and European guidelines, two recent key publications and larotrectinib data presented at the American Thyroid Association annual meeting.

Clinical takeaways:

NTRK fusions are more common in paediatric compared to adult thyroid cancers, testing is warranted in both populations
NTRK2 fusions have not been seen in thyroid cancer, only NTRK1 and NTRK3 fusions
Larotrectinib and entrectinib are two approved TRK inhibitors showing durable responses with favourable safety profiles
There are differences in the prognosis of NTRK1 vs NTRK3 fusion-positive thyroid cancer and differentiated vs anaplastic thyroid cancers

Prof. Ezra Cohen

Medical Oncologist

Moores Cancer Center, San Diego

United States (US)

Biography Disclosures

Prof. Ezra Cohen

Medical Oncologist

Moores Cancer Center, San Diego

United States (US)

Ezra Cohen, MD, is co‐Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician‐scientist, Dr Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer‐reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He has also recently co‐developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti‐tumor immune response. Dr Cohen is Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center’s Executive Committee. Dr Cohen recently served as editor‐in‐chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and currently serves as senior editor for Clinical Cancer Research. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr Cohen has authored more than 170 papers and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research. Dr Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr Cohen was Co‐Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/ Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr Cohen also mentored and developed young faculty in his program.

Prof. Ezra Cohen has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Gilead, Janssen, Kinnate Biopharma, Merck, Mirati, MSD, Regeneron and Roche.

NTRK fusions in thyroid cancer

time | open 5 min | Dec 2022

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download slides PDF

Download slides PPTX

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This educational programme is supported by an Independent Medical Education Grant from Bayer

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.

Other programmes of interest

Prof. Dimitrios Tsakiris

Dr Lars Asmis

Podcast

2 min

Cancer and Thrombosis

Sep 2023

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

5 min

Surveillance and Diagnosis of HCC in Asia: Poster Presentation at...

Sep 2023

Assoc. Prof. Gerald Prager

Video

4 min

Long-term Response in Advanced Colorectal Cancer

Sep 2023

Prof. Dr Jeroen Dekervel

Dr Amit Singal

Podcast

29 min

A New Era in Treating Patients with Advanced HCC

Sep 2023

Dr Jaume Capdevila

Asst. Prof. Mauro Cives

Micro learning

30 min

Accreditation: EACCME

Recognising, Diagnosing and Managing Neuroendocrine Tumours

Aug 2023

Acromegaly and Neuroendocrine Tumours Global Survey

Publication

15 min

Acromegaly and Neuroendocrine Tumours Global Survey

Aug 2023

Prof. Shaheenah Dawood

Assoc. Clinical Professor Rena Callahan

Podcast

74 min

Oral SERDs in ER+ Breast Cancer

Aug 2023

Dr Tracy L Stockley

Prof. David Hong

Podcast

24 min

An Introduction to Molecular Testing

Jul 2023

Dr Neal Shore

Dr Andrew J. Armstrong

Video

10 min

Clinical Implementation of Testing and PARPi as Monotherapy or in...

Aug 2023

Janet Forgenie

Video

3 min

Nursing Support for mCRPC Patients During Radiopharmaceutical Tre...

Jul 2023

Prof. Andrea Sartore-Bianchi

Video

5 min

Conference Update: ASCO and WCGIC 2023

Jul 2023

Other programmes developed by Prof. Ezra Cohen

Prof. Ezra Cohen

Medical Oncologist

Moores Cancer Center, San Diego

United States (US)

Prof. Ezra Cohen

Prof. Frédérique Penault-Llorca

Prof. Silvia Stacchiotti

And others...

30 min

TRK fusion-positive cancer: new ESMO OncologyPRO learning resourc...

Sep 2022

Prof. Ezra Cohen

5 min

NTRK CONNECT Update from ASCO 2020

May 2020

Prof. Ezra Cohen

5 min

Key Publication Snapshot 3 – Characterisation of adverse events...

Oct 2020

Prof. David Hong

Prof. Ezra Cohen

Prof. Frédérique Penault-Llorca

5 min

Accreditation: EACCME

Current opinions on how to identify and treat NTRK fusion positiv...

Jan 2021

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.